
Pfizer Inc.
PFEHealthcare|Drug Manufacturers - General|US
$29.39
-0.06 (-0.20%)
DCF Value
$37.35
Graham Number
$15.77
Cash / Share
$2.50
Next Earnings Report
Feb 2, 2027
EPS est. $0.69 · Revenue est. $17.14B
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Nov 20, 2025 (424B5). Possible dilution.
Upcoming Data Readouts (51)
Dec 2026
Est. completion
Dec 2026
Est. completion
P3Breast Cancer Recurrent
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
NCT03820830n=405
Dec 2026
Est. completion
P1Healthy Participants
A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
NCT07231991n=24
Dec 2026
Est. completion
P2Urothelial Carcinoma
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329n=372
Dec 2026
Est. completion
P3Breast Cancer
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
NCT05909397n=59
Dec 2026
Est. completion
Breast Cancer
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
NCT06495164n=1
Dec 2026
Est. completion
P2Lymphoma, Non-Hodgkin
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
NCT03297606n=720
Dec 2026
Est. completion
P4Metastatic Urothelial Carcinoma
A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
NCT06862219n=100
Dec 2026
Est. completion
P1P2Recurrent Solid Tumor
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
NCT04901702n=90
Jan 2027
Est. completion
P1P2Breast Cancer
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT04039230n=75
Jan 2027
Est. completion
P3Urothelial Carcinoma
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295n=412
Jan 2027
Est. completion
P2Stage III Breast Cancer
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT03971409n=145
Mar 2027
Est. completion
Metastatic Breast Cancer
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
NCT03275311n=42,000
Mar 2027
Est. completion
P1P2Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT05548127n=37
Jun 2027
Est. completion
P1Carcinoma, Non-Small Cell Lung
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632n=1,006
Jul 2027
Est. completion
Jul 2027
Est. completion
P2Smoldering Multiple Myeloma
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
NCT06183489n=50
Jul 2027
Est. completion
P1Myelodysplastic Syndrome
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847n=170
Jul 2027
Est. completion
P1Healthy
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
NCT07519135n=26
Aug 2027
Est. completion
P2Overweight
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932n=940
Awaiting Results (23)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2026
P2
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
NCT06106308May 2026
P3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435Mar 2026
P1
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
NCT05266105Sep 2025
P1P2
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837Recent Press Releases
Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
Nov 3, 2026 · Business Wire
Pfizer Appoints Cecile Guegan as Chief Financial Officer
Nov 3, 2026 · Business Wire
Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development
Oct 29, 2026 · Business Wire
Pfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
Oct 27, 2026 · Business Wire
Pfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
Oct 26, 2026 · Business Wire
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
Oct 24, 2026 · Business Wire
Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
Oct 14, 2026 · Business Wire
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules
Oct 13, 2026 · Business Wire
SEC Filings (74)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 3, 2026 | 8-K | Material event | DocumentIndex |
| Nov 3, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Nov 3, 2026 | 8-K | Material event | DocumentIndex |
| Oct 16, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Aug 31, 2026 | N-PX | DocumentIndex | |
| Aug 13, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Aug 4, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 4, 2026 | 8-K | Material event | DocumentIndex |
| Jun 18, 2026 | 8-K | Material event | DocumentIndex |
| Jun 18, 2026 | 8-K | Material event | DocumentIndex |
| Jun 16, 2026 | 11-K | DocumentIndex | |
| Jun 16, 2026 | 11-K | DocumentIndex | |
| May 12, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 12, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| May 5, 2026 | S-8 | Employee stock plan | DocumentIndex |
| May 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 5, 2026 | 8-K | Material event | DocumentIndex |
| Apr 27, 2026 | 8-K | Material event | DocumentIndex |
| Mar 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 12, 2026 | ARS | Annual report to holders | DocumentIndex |
| Mar 12, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Mar 12, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Feb 26, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 13, 2026 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| Feb 13, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 13, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 12, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Feb 3, 2026 | 8-K | Material event | DocumentIndex |
| Dec 16, 2025 | 8-K | Material event | DocumentIndex |
| Nov 21, 2025 | 8-K | Material event | DocumentIndex |
| Nov 20, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Nov 19, 2025 | FWP | DocumentIndex | |
| Nov 18, 2025 | 424B3 | Offering prospectus | DocumentIndex |
| Nov 13, 2025 | 13F-HR | Institutional holdings report | DocumentIndex |
| Nov 13, 2025 | 8-K | Material event | DocumentIndex |
| Nov 4, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 4, 2025 | 8-K | Material event | DocumentIndex |
| Aug 11, 2025 | 13F-HR | Institutional holdings report | DocumentIndex |
| Aug 5, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 5, 2025 | 8-K | Material event | DocumentIndex |